Skip to main content
Triangle logo TriangleGet started

Azacitidine (NCT06317649)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial): a one-minute explainerNCT063176491 min

Azacitidine trial for Acute Myeloid Leukemia (NCT06317649). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed acute myeloid leukemia carrying FLT3-ITD, D835 or I836del mutations, assigned through myeloMATCH. Patients are 60 or older, or younger adults judged better suited to lower-intensity treatment.

The idea: compare azacitidine plus venetoclax with two schedules adding oral gilteritinib. Venetoclax blocks a leukemia-cell survival protein; gilteritinib blocks FLT3 growth signals. Researchers compare remission without measurable residual disease. Prior hypomethylating drugs or FLT3 inhibitors are excluded.

This phase 2 study plans 147 patients. ECOG-ACRIN leads; 211 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.